Abstract:Elucidating genetic and epigenetic contributions to drug response variation is critical for the realization of personalized medicine, which may particularly benefit cancer patients, for whom anti-cancer agent-induced cytotoxicities are often major adverse reactions. Previous pharmacogenomic discoveries have utilized the HapMap lymphoblastoid cell line (LCL) model, on which the research community has accumulated extensive genotypic data and gene expression profiles. Given the complex nature of gene expression regulation, expanding the cell-based model to include epigenetic systems such as cytosine modifications has begun to allow novel pharmacoepigenetic studies that may enhance our understanding of drug response variation. Using a collection of the HapMap LCL samples, our team has profiled the genome-wide cytosine modification levels and explored the contribution of CpG modifications to anti-cancer agent-induced cytotoxicities. Specifically, in our recent pharmacogenomic study on clofarabine, we demonstrated that by integrating cytosine modifications, genetic variants, and gene expression phenotypes, we were able to significantly improve our ability to explain the phenotypic variance among individuals. Finally, advances in experimental techniques that can distinguish 5’-methylcytosine (5mC) and 5’-hydroxymethylcytosine (5hmC), the latter of which is a recently rediscovered nucleotide base in the human genome with potential unique biological functions, as well as stem cell technologies that can differentiate target tissues from induced pluripotent stem cells (iPSCs), will move forward the current pharmacoepigenetic and pharmacogenomic research to the next stage with higher molecular resolution and better clinical relevance.

Study advance in tumor pharmacogenomics

Pharmacogenomics and Individualized Medication

Pharmacogenomics on anti-cancer drugs: research advances

Advances of pharmacogenomics in colorectal cancer

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Gene targeting tailored therapy for the anti-tumor drugs

Pharmacogenetics Of Cancer Therapy: Breakthroughs From Beyond?

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Personalized medicine:current status, challenges and strategies

The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

Pharmacogenomics--genomics approaches to optimizing drug therapy

Pharmacoepigenetics Explores the Epigenetic Contribution to Anti-Cancer Agent-Induced Cytotoxicities

Clinical cancer genomics and personalized treatment

Advancement in pharmacogentics and hypenteasion medicine

New Era of Individualized Pharmacotherapy

Comes of Age:Individualized Medicine in Cancer Therapy

Translating Pharmacogenomics into Personalized Medicine and Drug Development.

Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine

Pharmacogenomics of Platinum-Based Chemotherapy Sensitivity in NSCLC: Toward Precision Medicine.